These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Itching nodules and hypersensitivity to aluminium after the use of adsorbed vaccines from SSI. Thierry-Carstensen B; Stellfeld M Vaccine; 2004 May; 22(15-16):1845. PubMed ID: 15121293 [No Abstract] [Full Text] [Related]
5. When an aluminium adjuvant is not an aluminium adjuvant used in human vaccination programmes. Exley C Vaccine; 2012 Mar; 30(12):2042. PubMed ID: 22041301 [No Abstract] [Full Text] [Related]
6. Aluminum vaccine adjuvants: are they safe? Tomljenovic L; Shaw CA Curr Med Chem; 2011; 18(17):2630-7. PubMed ID: 21568886 [TBL] [Abstract][Full Text] [Related]
7. Public health. Aluminum is put on trial as a vaccine booster. Malakoff D Science; 2000 May; 288(5470):1323-4. PubMed ID: 10847840 [No Abstract] [Full Text] [Related]
9. Reviewing the association between aluminum adjuvants in the vaccines and autism spectrum disorder. Boretti A J Trace Elem Med Biol; 2021 Jul; 66():126764. PubMed ID: 33930617 [TBL] [Abstract][Full Text] [Related]
11. Aluminum adjuvant dose guidelines in vaccine formulation for preclinical evaluations. Vecchi S; Bufali S; Skibinski DA; O'Hagan DT; Singh M J Pharm Sci; 2012 Jan; 101(1):17-20. PubMed ID: 21918987 [TBL] [Abstract][Full Text] [Related]
12. Vaccine adjuvant safety: the elephant in the room. Petrovsky N Expert Rev Vaccines; 2013 Jul; 12(7):715-7. PubMed ID: 23885815 [No Abstract] [Full Text] [Related]
13. [Aluminium adjuvant exposure through vaccines in France in 2018]. Angrand L; Elnar AA; Authier FJ; Gherardi RK; Crépeaux G Ann Pharm Fr; 2020 Mar; 78(2):111-128. PubMed ID: 32081303 [TBL] [Abstract][Full Text] [Related]
14. [Macrophage mediated myofasciites: a systemic disease or post-vaccinial tatoo?]. Papo T Rev Neurol (Paris); 2007 Oct; 163(10):981-4. PubMed ID: 18033037 [No Abstract] [Full Text] [Related]
15. Vaccine adjuvants. Macy DW Semin Vet Med Surg Small Anim; 1997 Aug; 12(3):206-11. PubMed ID: 9283246 [TBL] [Abstract][Full Text] [Related]
16. A need for effective adjuvants. Bunce CJ; Morse MA Curr Opin Mol Ther; 2003 Feb; 5(1):8-9. PubMed ID: 12669464 [No Abstract] [Full Text] [Related]
17. The path to a successful vaccine adjuvant--'the long and winding road'. O'Hagan DT; De Gregorio E Drug Discov Today; 2009 Jun; 14(11-12):541-51. PubMed ID: 19508916 [TBL] [Abstract][Full Text] [Related]